To include your compound in the COVID-19 Resource Center, submit it here.

ADC reports Phase I data for ADCT-301 in Hodgkin's lymphoma

ADC Therapeutics S.A. (Epalinges, Switzerland) reported interim data from 35 evaluable patients with Hodgkin's lymphoma in a Phase I trial

Read the full 206 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE